Loading...
The immunomodulatory drug lenalidomide (L) plus weekly dexamethasone (d) is a standard induction regimen (Ld) for patients with myeloma who are ineligible for autologous stem cell transplant (SCT) consolidation therapy. Now, investigators report an interim analysis of a phase III, multicenter, pharmaceutical company–sponsored trial in which newly diagnosed patients were randomized to ongoing 28-day cycles of Ld alone (the control group) or Ld plus the anti-CD38 monoclonal antibody daratumumab (LdD, the intervention group); treatment continued until toxicity or disease progression occurred.
A total of 737 patients were randomized equally to receive a median of 27 LdD cycles versus 22 Ld cycles. During a median follow-up period of 28 months, d…